Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma - PubMed (original) (raw)
Clinical Trial
. 1998 Jun;16(6):2169-80.
doi: 10.1200/JCO.1998.16.6.2169.
Affiliations
- PMID: 9626218
- DOI: 10.1200/JCO.1998.16.6.2169
Clinical Trial
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
A L Yu et al. J Clin Oncol. 1998 Jun.
Abstract
Purpose: To evaluate the toxicity, immunogenicity, and pharmacokinetics of a human-mouse chimeric monoclonal antibody (mAb) ch 14.18 directed against disialoganglioside (GD2) and to obtain preliminary information on its clinical efficacy, we conducted a phase I trial in 10 patients with refractory neuroblastoma and one patient with osteosarcoma.
Patients and methods: Eleven patients were entered onto this phase I trial. They received 20 courses of mAb ch 14.18 at dose levels of 10, 20, 50, 100, and 200 mg/m2. Dose escalation was performed in cohorts of three patients; intrapatient dose escalation was also permitted.
Results: The most prevalent toxicities were pain, tachycardia, hypertension, fever, and urticaria. Most of these toxicities were dose-dependent and rarely noted at dosages of 20 mg/m2 and less. Although the maximum-tolerated dose was not reached in this study, clinical responses were observed. These included one partial (PR) and four mixed responses (MRs) and one stable disease (SD) among 10 assessable patients. Biologic activity of ch 14.18 in vivo was shown by binding of ch 14.18 to tumor cells and complement-dependent cytotoxicity of posttreatment sera against tumor target cells. An anti-ch 14.18 immune response was detectable in seven of 10 patients studied.
Conclusion: In summary, with the dose schedule used, ch 14.18 appears to be clinically safe and effective, and repeated mAb administration was not associated with increased toxicities. Further clinical trials of mAb ch 14.18 in patients with neuroblastoma are warranted.
Similar articles
- Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN. Zeng Y, et al. Mol Immunol. 2005 Jul;42(11):1311-9. doi: 10.1016/j.molimm.2004.12.018. Epub 2005 Apr 7. Mol Immunol. 2005. PMID: 15950727 - Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, et al. Murray JL, et al. J Clin Oncol. 1994 Jan;12(1):184-93. doi: 10.1200/JCO.1994.12.1.184. J Clin Oncol. 1994. PMID: 8270976 Clinical Trial. - Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM, Hank JA. Sondel PM, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Cancer J Sci Am. 1997. PMID: 9457407 Review. - Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K, Bernhardt B, Strickland B. Parsons K, et al. Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386066 Review.
Cited by
- Advances on immunotherapy for osteosarcoma.
Yu S, Yao X. Yu S, et al. Mol Cancer. 2024 Sep 9;23(1):192. doi: 10.1186/s12943-024-02105-9. Mol Cancer. 2024. PMID: 39245737 Free PMC article. Review. - GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review. - A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO.
Trautwein NF, Schwenck J, Seitz C, Seith F, Calderón E, von Beschwitz S, Singer S, Reischl G, Handgretinger R, Schäfer J, Lang P, Pichler BJ, Schulte JH, la Fougère C, Dittmann H. Trautwein NF, et al. Theranostics. 2024 Jan 20;14(3):1212-1223. doi: 10.7150/thno.92481. eCollection 2024. Theranostics. 2024. PMID: 38323317 Free PMC article. - Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Laopajon W, Takheaw N, Kotemul K, Pata S, Hongeng S, Kasinrerk W. Laopajon W, et al. Explor Target Antitumor Ther. 2023;4(6):1145-1156. doi: 10.37349/etat.2023.00188. Epub 2023 Dec 6. Explor Target Antitumor Ther. 2023. PMID: 38213540 Free PMC article. - Targeting the myeloid microenvironment in neuroblastoma.
Stip MC, Teeuwen L, Dierselhuis MP, Leusen JHW, Krijgsman D. Stip MC, et al. J Exp Clin Cancer Res. 2023 Dec 13;42(1):337. doi: 10.1186/s13046-023-02913-9. J Exp Clin Cancer Res. 2023. PMID: 38087370 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials